Education
About Us
Working with TipRanks
Follow Us
ImmuPharma PLC (GB:IMM)
LSE:IMM
Total Valuation
ImmuPharma has a market cap or net worth of £26.64M. The enterprise value is 10.64M.
Market Cap£26.64M
Enterprise Value10.64M
Share Statistics
ImmuPharma has 502,723,940 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding502,723,940
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
ImmuPharma’s return on equity (ROE) is 4.57 and return on invested capital (ROIC) is 464.71%.
Return on Equity (ROE)4.57
Return on Assets (ROA)-2.54
Return on Invested Capital (ROIC)464.71%
Return on Capital Employed (ROCE)4.20
Revenue Per Employee0.00
Profits Per Employee-496.70K
Employee Count5
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of ImmuPharma is ―. ImmuPharma’s PEG ratio is 0.08.
PE Ratio―
PS Ratio0.00
PB Ratio-9.23
Price to Fair Value-9.23
Price to FCF-2.83
Price to Operating Cash Flow-25.24
PEG Ratio0.08
Income Statement
In the last 12 months, ImmuPharma had revenue of 0.00 and earned -2.48M in profits. Earnings per share was -0.01.
Revenue0.00
Gross Profit-63.88K
Operating Income-2.28M
Pretax Income-2.78M
Net Income-2.48M
EBITDA-2.61M
Earnings Per Share (EPS)-0.01
Cash Flow
In the last 12 months, operating cash flow was -1.90M and capital expenditures -1.65K, giving a free cash flow of -1.90M billion.
Operating Cash Flow-1.90M
Free Cash Flow-1.90M
Free Cash Flow per Share>-0.01
Dividends & Yields
ImmuPharma pays an annual dividend of 1p, resulting in a dividend yield of ―
Dividend Per Share1p
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.26
52-Week Price Change379.67%
50-Day Moving Average8.73
200-Day Moving Average5.35
Relative Strength Index (RSI)35.96
Average Volume (3m)15.00M
Important Dates
ImmuPharma upcoming earnings date is May 26, 2026, TBA (Confirmed).
Last Earnings DateAug 6, 2025
Next Earnings DateMay 26, 2026
Ex-Dividend Date―
Financial Position
ImmuPharma as a current ratio of 0.58, with Debt / Equity ratio of 0.00%
Current Ratio0.58
Quick Ratio0.58
Debt to Market Cap0.00
Net Debt to EBITDA0.09
Interest Coverage Ratio-1.15K
Taxes
In the past 12 months, ImmuPharma has paid -295.87K in taxes.
Income Tax-295.87K
Effective Tax Rate-0.11
Enterprise Valuation
ImmuPharma EV to EBITDA ratio is -1.83, with an EV/FCF ratio of -2.69.
EV to Sales0.00
EV to EBITDA-1.83
EV to Free Cash Flow-2.69
EV to Operating Cash Flow-2.70
Balance Sheet
ImmuPharma has £396.65K in cash and marketable securities with £0.00 in debt, giving a net cash position of £396.65K billion.
Cash & Marketable Securities£396.65K
Total Debt£0.00
Net Cash£396.65K
Net Cash Per Share<£0.01
Tangible Book Value Per Share>-£0.01
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for ImmuPharma is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―